Affiliation:
1. Unilever Dental Research, United Kingdom.
Abstract
Mutacin II is an antibiotic that is produced by group II Streptococcus mutans. It inhibits the growth of other streptococci as well as many other gram-positive microorganisms by a hitherto unknown mechanism. Mutacin II possess bactericidal activity against susceptible cells. It transiently depolarizes the transmembrane electrical potential (delta psi) and the transmembrane pH gradient (delta pH) and partially inhibits amino acid transport. However, it rapidly depletes the intracellular ATP pool in glucose-energized cells and prevents the generation of ATP. It is concluded that mutacin II does not belong to the group of pore-forming antibiotics (type A) or to the type B antibiotics, which inhibit phospholipases or interfere with peptidoglycan biosynthesis. Mutacin II acts by inhibiting essential enzyme functions at the level of metabolic energy generation, an activity that has not yet been classified for antibiotics.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference34 articles.
1. Au V. R. G. Carson B. Harirchian and K. M. Schilling. 1994. Oral hygiene compositions containing antiplaque agents. U.S. patent 5 310 542. Lever Brothers Company.
2. Chikindas M. L. 1995. Unpublished results.
3. Pediocin PA-1, a bacteriocin from Pediococcus acidilactici PAC1.0, forms hydrophilic pores in the cytoplasmic membrane of target cells;Chikindas M. L.;Appl. Environ. Microbiol.,1993
4. Two plasmid-determined restriction and modification systems in Streptococcus lactis;Chopin A.;Plasmid,1984
5. Doel G. 1993. Dentifrice compositions. PCT/international patent application. International publication number WO 93/11738. SmithKline Beecham PLC United Kingdom.
Cited by
50 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献